ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2
暂无分享,去创建一个
[1] David W. Miller,et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.
[2] C. Olanow,et al. Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.
[3] N. Gray,et al. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.
[4] L. Petrucelli,et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity , 2009, Proceedings of the National Academy of Sciences.
[5] M. Ueffing,et al. ARHGEF7 (BETA-PIX) Acts as Guanine Nucleotide Exchange Factor for Leucine-Rich Repeat Kinase 2 , 2010, PloS one.
[6] J. Cherfils,et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.
[7] L. Petrucelli,et al. Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease , 2010, Nature Medicine.
[8] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[9] K. Lim,et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.
[10] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[11] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Ross,et al. A Drosophila model for LRRK2-linked parkinsonism , 2008, Proceedings of the National Academy of Sciences.
[13] C. Ross,et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.
[14] R. Kahn,et al. Models for the functions of Arf GAPs. , 2011, Seminars in cell & developmental biology.
[15] K. Lim,et al. Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila , 2009, The Journal of Neuroscience.
[16] D. Lambright,et al. Rab GEFs and GAPs. , 2010, Current opinion in cell biology.
[17] M. Cookson,et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.
[18] Andrew B West,et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Mattson,et al. The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior , 2011, Cell.
[20] P. Emson,et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.
[21] V. Budnik,et al. Catecholamine‐containing neurons in Drosophila melanogaster: Distribution and development , 1988, The Journal of comparative neurology.
[22] N. Hattori,et al. LRRK2 regulates synaptic vesicle endocytosis. , 2008, Experimental cell research.
[23] Jay Hirsh,et al. Targeted gene expression in Drosophila dopaminergic cells using regulatory sequences from tyrosine hydroxylase. , 2003, Journal of neurobiology.
[24] T. Dawson,et al. Inhibitors of LRRK 2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson ’ s disease models , 2011 .
[25] Christopher A Ross,et al. Widespread expression of Huntington's disease gene (IT15) protein product , 1995, Neuron.
[26] Shu G. Chen,et al. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.
[27] A. Gitler,et al. GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 , 2010, PLoS genetics.
[28] Matthew J. Farrer,et al. LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.
[29] T. Dawson,et al. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. , 2011, Human molecular genetics.
[30] Mark R. Cookson,et al. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.